Report Overview

The European Lung Cancer Therapeutics market size stood at USD 1.67 billion in 2020 and is expected to rise to USD 2.76 billion by the end of 2028 exhibiting a CAGR of approximately 6.47% during the forecast period.

Lung Cancer is the foremost cause of cancer deaths in the European region. A study by Karolinska Institutet has established that ten Swedes die of lung cancer every day. Rise in awareness and the emergence of new medical diagnostic equipment have increased the number of diagnoses, thus propelling the growth of lung cancer therapeutics market. While smoking is the predominant reason accounting to 85 percent of all the lung cancer occurrences, several other factors like genetic predisposition and exposure to carcinogens also count as causes.



Market Drivers

Lung Cancer Therapeutics market in Sweden is mainly driven by the increase in prevalence of Lung cancer cases owing to the rise in usage of smoking tobacco products. While this is a major reason for lung cancer, people getting constantly exposed to carcinogens and radiation also contribute to the cause. The delay in identification of lung cancers lead to late diagnosis- increasing the healthcare expenditure which in turn drives market growth.

In the recent times, people have grown increasingly aware of the disease and its complications, driving them to seek medical care which is another reason for market growth.